Skip to main content

SNDX

Stock
Health Care
Biotechnology

Performance overview

SNDX Price
Price Chart

Forward-looking statistics

Beta
1.03
Risk
53.39%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.

Company info

SectorHealth Care
IndustryBiotechnology
Employees148
Market cap$1.7B

Fundamentals

Enterprise value$635.2M
Revenue$43.7M
Revenue per employee
Profit margin96.51%
Debt to equity160.71

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.85
Dividend per share
Revenue per share$0.51
Avg trading volume (30 day)$21M
Avg trading volume (10 day)$22M
Put-call ratio

Macro factor sensitivity

Growth-0.3
Credit+6.9
Liquidity-0.8
Inflation-3.5
Commodities-0.0
Interest Rates-1.5

Valuation

Dividend yield0.00%
PEG Ratio-2.54
Price to sales17.71
P/E Ratio-2.54
Enterprise Value to Revenue14.53
Price to book3.60

Upcoming events

Next earnings dayMay 6, 2025
Next dividend day
Ex. dividend day

News

Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?

The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research (May 9, 2025)
Under-the-radar biotech bets

Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.

CNBC Television (April 3, 2024)
Syndax Pharma Posts Additional Data On Clinical Activity, Responses From Early-Stage Leukemia Trial

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed-lineage leukemia rearranged (MLLr) relapsed/refractory acute leukemias. The data were featured at the American Society of Hematology (ASH) Annual Meeting.

Benzinga (December 14, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free